Uncategorized
Clearside enrolls first patient in CLS-TA phase 3 clinical trial
Clearside Biomedical enrolled its first patient for the phase 3 clinical trial of CLS-TA to treat macular edema associated with noninfectious uveitis, according to a company press release.The phase 3 Peachtree clinical trial to evaluate efficacy of 4 mg CLS-TA (triamcinolone acetonide) delivered via the suprachoroidal space is set to last 6 months. The trial is randomized, masked and sham-controlled with a clinical endpoint at 24 weeks of a 15-letter change in best corrected visual acuity from baseline. The company expects approximately 150 patients to enroll across 50 sites.